CTI wins over FDA to claim early review of myelofibrosis drugShares in US biotech CTI BioPharma have shot up after the FDA agreed to an accelerated review early Share XCTI wins over FDA to claim early review of myelofibrosis drughttps://pharmaphorum.com/news/cti-wins-over-fda-to-claim-early-review-of-myelofibrosis-drug/
Blank cheque company merger creates cancer specialist VinceraLifeSci Acquisition – a so-called ‘blank cheque’ company – has announced a $60 million merger with Vincera Pharma Share XBlank cheque company merger creates cancer specialist Vincerahttps://pharmaphorum.com/news/blank-cheque-company-merger-creates-cancer-specialist-vincera/
Clinical decision-making insights for haematologists and oncologistsClinical trial readouts continue to emerge despite countries’ lockdown policies, providing several decision-making challenges for healthcare professionals such Share XClinical decision-making insights for haematologists and oncologistshttps://pharmaphorum.com/views-analysis-digital/clinical-decision-making-insights-for-haematologists-and-oncologists/
Takeda’s bleeding disorder drug Veyvondi backed for NHS useNHS England has recommended that patients with von Willebrand disease (VWD) be treated with Takeda’s Veyvondi, making it Share XTakeda’s bleeding disorder drug Veyvondi backed for NHS usehttps://pharmaphorum.com/news/takedas-bleeding-disorder-drug-veyvondi-backed-for-nhs-use/
GSK moves further ahead in BCMA with EU okay for BlenrepGlaxoSmithKline has approval on both sides of the Atlantic for its multiple myeloma drug Blenrep, after getting the Share XGSK moves further ahead in BCMA with EU okay for Blenrephttps://pharmaphorum.com/news/gsk-moves-further-ahead-in-bcma-with-eu-okay-for-blenrep/
Novartis eyes filings for leukaemia drug asciminib after phase 3 winA first-in-class STAMP inhibitor developed by Novartis – asciminib – has outperformed a current drug for chronic myeloid Share XNovartis eyes filings for leukaemia drug asciminib after phase 3 winhttps://pharmaphorum.com/news/novartis-eyes-filings-for-leukaemia-drug-asciminib-after-phase-3-win/
How to increase haematologists’ and oncologists’ confidence with new treatmentsA new whitepaper from Medscape highlights the difficulties haematologists and oncologists face in keeping up with rapid developments Share XHow to increase haematologists’ and oncologists’ confidence with new treatmentshttps://deep-dive.pharmaphorum.com/magazine/future-of-oncology-2020/how-to-increase-haematologists-and-oncologists-confidence-with-new-treatments/
Clinical decision-making insights for haem/oncsDespite the effects of countries’ lockdown policies, a plethora of clinical trial readouts continue to emerge providing several Share XClinical decision-making insights for haem/oncshttps://pharmaphorum.com/oncology/clinical-decision-making-insights-haem-oncs/
Scopus Bio preps trials of gene-silencing immuno-oncology drugScopus BioPharma has licensed a gene-silencing drug from California’s City of Hope hospital that is due to start Share XScopus Bio preps trials of gene-silencing immuno-oncology drughttps://pharmaphorum.com/news/scopus-bio-preps-trials-of-gene-silencing-immuno-oncology-drug/
